PFS Partners’s Trevi Therapeutics TRVI Stock Holding History

PFS Partners’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$942K	Hold	79,000	–	–	0.43%	29
2025 Q4	$989K	Hold	79,000	–	–	0.45%	28
2025 Q3	$723K	Hold	79,000	–	–	0.34%	31
2025 Q2	$432K	Hold	79,000	–	–	0.22%	40
2025 Q1	$497K	Hold	79,000	–	–	0.26%	35
2024 Q4	$325K	Hold	79,000	–	–	0.17%	48
2024 Q3	$264K	Hold	79,000	–	–	0.15%	51
2024 Q2	$235K	Sell	79,000 -20,000	-20%	-$55.6K	0.15%	53
2024 Q1	$342K	Hold	99,000	–	–	0.23%	37
2023 Q4	$133K	Sell	99,000 -1,000	-1%	-$1.51K	0.09%	72
2023 Q3	$218K	Hold	100,000	–	–	0.19%	36
2023 Q2	$239K	Buy	+100,000	New	+$252K	0.2%	34

Other funds holding TRVI

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return